Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 14, 2007, Pages 4775-4799

  Gu, Keli ^a   Bi, Lanrong ^a   Zhao, Ming ^a   Wang, Chao ^b   Ju, Jingfang ^c   Peng, Shiqi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c Mitchell Cancer Institute   (United States)

Author keywords

2,5 Disubstituted dioxacycloalkanes; Anti inflammatory activity; Chemoprevention agents; Stereoselective synthesis; Structure activity relationship study

Indexed keywords

(2 PHENYL 1,3 DIOXAN 5 YL)BENZAMIDE; (2 PHENYL 1,3 DIOXAN 5 YL)PHENYLACETAMIDE; (2 PHENYL 4 METHYL 1,3 DIOXAN 5 YL)BENZAMIDE; (2 PHENYL 4 METHYL 1,3 DIOXAN 5 YL)PHENYLACETAMIDE; 2 (3' NITROPHENYL 1,3 DIOXAHEPTAN 5 YL)PHENYLACETAMIDE; 2 (4 CHLOROPHENYL 1,3 DIOXAHEPTAN 5 YL)BENZAMIDE; 2 (4' CHLOROPHENYL 1,3 DIOXAHEPTAN 5 YL)PHENYLACETAMIDE; 2 (4' NITROPHENYL 1,3 DIOXAHEPTAN 5 YL)PHENYLACETAMIDE; 2 [(3' NITROPHENYL) 1,3 DIOXAN 5 YL]BENZAMIDE; 2 [(3' NITROPHENYL) 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; 2 [(4' CHLOROPHENYL) 1,3 DIOXAN 5 YL]BENZAMIDE; 2 [(4' METHYLPHENYL) 1,3 DIOXAN 5 YL]BENZAMIDE; 2 [(4' NITROPHENYL) 1,3 DIOXAN 5 YL]BENZAMIDE; 2 [(4' NITROPHENYL) 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (3' NITROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (3' NITROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (4' CHLOROPHENYL) 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (4' CHLOROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (4' CHLOROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (4' METHYLPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (4' METHYLPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (4' NITROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (4' NITROPHENYL) 4 METHYL 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (PHENYLVINYL) 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (PHENYLVINYL) 1,3 DIOXAN 5 YL]PHENYLACETAMIDE; [2 (PHENYLVINYL) 4 METHYL 1,3 DIOXAN 5 YL]BENZAMIDE; [2 (PHENYLVINYL) 4 METHYL 1,3 DIOXAN 5 YL]PHENYLACETYLAMIDE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; EAR; EDEMA; MALE; MOUSE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLEEDING TIME; CHEMOPREVENTION; CYCLOPARAFFINS; DRUG DESIGN; EDEMA; MALE; MICE; MOLECULAR STRUCTURE; OXYGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 34249736342     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.05.013     Document Type: Article

References (30)

1. Arber N., and Levin B. Recent Results Cancer Res. 166 (2005) 213-230
2. Lippman S.M., Lee J.J., and Sabichi A.L. J. Natl. Cancer Inst. 90 (1998) 1514-1528
3. Heavey P.M., kenna D.Mc., and Rowland I.R. Nutr. Cancer 48 (2004) 124-141
4. Asano T.K., and Leod R.S.Mc. Dis. Colon Rectum 47 (2004) 665-673
5. Kune G.A. Aust. N. Z. J. Surg. 70 (2000) 452-455
6. Huls G., Koornstra J.J., and Kleibeuker J.H. Lancet 362 (2003) 230-232
7. Tarnawski A.S., and Jmes M.K. J. Mol. Med. 81 (2003) 627-636
8. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. FASEB J. 15 (2001) 2742-2744
9. Jiang, J. B.; Johnson, M. G.; Nichols, J. US Patent 5,360,818, 1994.
10. Shi R.X., Ong C.N., and Shen H.M. Cancer Res. 65 (2005) 7815
11. Pan Q., Bao L.W., Kleer C.G., Sable M.S., Griffith K.A., Teknos T.N., and Merajver S.D. Cancer Res. 65 (2005) 8366
12. Aksoy E., Goldman M., and Willems F. Int. J. Biochem. Cell Biol. 36 (2004) 183
13. Hanlon P.R., Fy P., Wright G.L., Steenbergen C., Arcasoy M.O., and Murphy E. FASEB J. 19 (2005) 1323
14. Churchill E.N., Murrile C.L., Chen C.L., Mochly-Rosen D., and Szweda L.I. Circ. Res. 97 (2005) 78
15. Bi L., Zhao M., Wang C., and Peng S. Eur. J. Org. Chem. (2000) 2669-2676
16. Bi L., Zhao M., Wang C., Peng S., and Winterfeldt E. J. Org. Chem. 67 (2002) 22-26
17. Bi L., Zhang Y., Zhao M., Wang C., Tok J., and Peng S. Bioorg. Med. Chem. 13 (2005) 5640
18. Gu K., Bi L., Zhao M., Wang C., Kao M., Tok J., and Peng S. Bioorg. Med. Chem. 14 (2006) 1339
19. Romay C., Armesto J., Remirez D., Gonzalez R., Ledon N., and Garcia I. Inflamm. Res. 47 (1998) 334
20. Smith A.B., Cho Y.S., Zawacki L.E., Hirschmann R., and Pettit G.R. Org. Lett. 3 (2001) 4063
21. Moore R.A., Derry S., Phillips C.J., and Mcquay H.J. BMC Musculoskelet. Disord. 20 (2006) 79
22. Garcia-Rodriguez L.A., and Jick H. Lancet 343 (1994) 769-772
23. Zhang K., Young C., and Berger J. J. Manag. Care Pharm. 12 (2006) 640-648
24. Kargman S., Charleson S., Cartwright M., et al. Gastroenterology 111 (1996) 445-454
25. Grossman C.J., Wiseman J., and Lucas F.S. Inflamm. Res. 44 (1995) 253-257
26. Funk C.D., Funk L.B., Kennedy M.E., et al. FASEB J. 5 (1991) 2304-2312
27. Gallagher J.E., Blauth J., and Fornadley J.A. Laryngoscope 105 (1995) 606-609
28. Conrad K., Fagan T., Mackie M., et al. Clin. Pharmacol. Ther. 43 (1988) 542-546
29. Spowart K., Greer A., McLaren M., et al. Thromb. Haemost. 60 (1988) 382-386
30. Dejana F., Villa S., and Dc Gaetano G. Thromb. Haemost. 48 (1982) 108-110